Ionis enters exclusive licensing agreement with bicycle therapeutics aimed at further advancing lica technology

Carlsbad, calif., july 13, 2021 /prnewswire/ -- ionis pharmaceuticals, inc. (nasdaq: ions) today announced that it has entered into an exclusive licensing agreement with bicycle therapeutics plc (nasdaq: bcyc) to increase the delivery capabilities of ionis' advanced ligand conjugated antisense (lica) medicines.
BCYC Ratings Summary
BCYC Quant Ranking